Dr. Sammy Saab, MD

Dr. Saab practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Saab's NPI, 1720008899, was assigned on July 20, 2006. Dr. Saab graduated from David Geffen School of Medicine at UCLA in 1993. Dr. Saab holds California license G80181.

Dr. Saab's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Saab's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Saab is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Saab to 2 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saab practices, 6 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Saab's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Saab is board certified in transplant hepatology by the American Board of Internal Medicine. Dr. Saab is licensed in California.

Dmand AI lists acute kidney failure, chronic anemia, cirrhosis of the liver, fatty liver, hemorrhoids, immune deficiency disease, muscle pain, fibromyalgia, and limb pain and nerve damage among the conditions Dr. Saab treats.

CMS data shows 1,177 Medicare services from Dr. Saab across 6 procedure codes in 2024, for 639 Medicare patients. Medicare paid $88,362 for them.

CMS counts 639 Medicare patients who saw Dr. Saab in 2024. The largest group is 65 to 74, with 327 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 45% are also on Medicaid. Their average risk score is 2.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Saab's median patient age at 61, with 49% women.

In 2024, Dr. Saab wrote 1,051 Medicare Part D claims for 191 patients. 68% of them were for generic drugs. CMS names the drug for 927 of them, across 18 drugs with 11 or more claims each, at $810,151 in total drug cost. In 2023, CMS named 900 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Saab for performance year 2024, reported as part of a group. Dr. Saab accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Saab as offering telehealth.

Dmand AI links 69 papers to Dr. Saab, published from 2003 to 2025. 2015 was the busiest year, with 9. The most frequent topics are Liver Transplantation and Hepatitis C. Dr. Saab's most frequent co-authors are Jose M. Nieto, DO, Douglas G. Farmer, MD and Vatche Garen Agopian, MD.

Dmand AI links Dr. Saab to 1 clinical trial. Conditions studied include Hepatitis C, Chronic and Hepatitis, Chronic.

CMS Open Payments shows 2,831 general payments to Dr. Saab from 38 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 58% of the total. Gilead Sciences, Inc. paid the most, $805,110.

Dmand AI lists 4 awards for Dr. Saab, most recently Top Doctors:LA Area in 2013.

Dr. Saab graduated from David Geffen School of Medicine at UCLA in 1993. Dr. Saab is a member of ACG and AGA.

Dr. Saab is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.